Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
暂无分享,去创建一个
Vladimir P Torchilin | V. Torchilin | A. Lukyanov | Tamer A Elbayoumi | A. Chakilam | T. Elbayoumi | Anatoly N Lukyanov | Ananthsrinivas R Chakilam | Ananthsrinivas R. Chakilam
[1] S. Takeoka,et al. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. , 2000, Bioconjugate chemistry.
[2] Z. Amoura,et al. Binding of nucleosomes to a cell surface receptor: Redistribution and endocytosis in the presence of lupus antibodies , 1996, European journal of immunology.
[3] R. Gaspar,et al. Use of the Post-Insertion Technique to Insert Peptide Ligands into Pre-Formed Stealth Liposomes with Retention of Binding Activity and Cytotoxicity , 2002, Pharmaceutical Research.
[4] A. Gabizon. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.
[5] S. Groshen,et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] R. Gaspar,et al. A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. , 2001, Biochimica et biophysica acta.
[7] D. Bell,et al. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. , 1991, Clinical immunology and immunopathology.
[8] V. Torchilin,et al. Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. , 1995, Immunology letters.
[9] J. Markovits,et al. A monoclonal anti-double-stranded DNA autoantibody binds to a 94-kDa cell-surface protein on various cell types via nucleosomes or a DNA-histone complex. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[10] V. Torchilin,et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.
[11] S. Kennedy,et al. A fluorescence-based protein assay for use with a microplate reader. , 1993, Analytical biochemistry.
[12] R. Haugland. Coupling of monoclonal antibodies with fluorophores. , 1995, Methods in molecular biology.
[13] V. Torchilin,et al. Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens. , 1985, Analytical biochemistry.
[14] E. Moase,et al. Use of the post-insertion method for the formation of ligand-coupled liposomes. , 2002, Cellular & molecular biology letters.
[15] Torchilin Vp,et al. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. , 1997, Oncology research.
[16] G Blume,et al. Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.
[17] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[18] P. Low,et al. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. , 1995, Biochimica et biophysica acta.
[19] K. Skubitz. Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma* , 2003, Cancer investigation.
[20] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[21] V. Torchilin,et al. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. , 1998, Cancer detection and prevention.
[22] U. Nielsen,et al. Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[23] G Gregoriadis,et al. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.
[24] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[25] V. Torchilin,et al. Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .
[26] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[27] D. Tzemach,et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.
[28] Vladimir P. Torchilin,et al. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[29] D. Tzemach,et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] T. Ishida,et al. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs , 1999, FEBS letters.
[31] V. Torchilin,et al. ATP-containing immunoliposomes specific for cardiac myosin. , 2004, Current drug delivery.
[32] Ananth Annapragada,et al. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. , 2003, Journal of controlled release : official journal of the Controlled Release Society.